12:05 PM EST - Fennec Pharmaceuticals Inc : Today announced that the U.S. Food and Drug Administration has approved PEDMARK®, a sodium thiosulfate injection, to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors. This approval makes PEDMARK the first and only treatment approved by the FDA in this area of significant unmet medical need. Fennec Pharmaceuticals Inc
shares T.FRX are trading up $0.94 at $10.88.
